PROFILBARU.COM

PNU-22394
Identifiers
	IUPAC name 6-Methyl-1,2,3,4,5,6-hexahydro-azepino[4,5-b]indole;
CAS Number	15923-78-1 ;
PubChem CID	27559;
ChemSpider	25649 ;
UNII	J7HPJ854EA;
ChEMBL	ChEMBL6557 ;
CompTox Dashboard (EPA)	DTXSID001028489 ;
Chemical and physical data
Formula	C13H16N2
Molar mass	200.285 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C3CNCCc2c3c1ccccc1n2C;
	InChI InChI=1S/C13H16N2/c1-15-12-5-3-2-4-10(12)11-6-8-14-9-7-13(11)15/h2-5,14H,6-9H2,1H3 ; Key:ZBXDOQWPGBISAR-UHFFFAOYSA-N ;
	(what is this?) (verify)

PNU-22394 is a drug which acts as an agonist at serotonin 5-HT₂ receptors, with strongest binding affinity for 5-HT_2A and 5-HT_2C and slightly weaker at 5-HT_2B, although it is only a full agonist at 5-HT_2C, but partial agonist at 5-HT_2A and 5-HT_2B. It has anorectic effects in both animal studies and human trials,^[1]^[2] along with "Pro-Cognitive Properties",^[3] although it has never been developed for medical use.

References

^ McCall RB, Franklin SR, Hyslop DK, Knauer CS, Chio CL, Haber CL, Fitzgerald LW (2001). "PNU-22394, a 5-HT2C receptor agonist, reduced feeding in rodents and produces weight loss in humans" (Online). 27 (309.2). Presentation Number 309.2. Convention Center Exhibit Hall, Poster Board TT-45, San Diego, CA: Society for Neuroscience Abstracts. Retrieved 18 July 2014. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: location (link)
^ Garfield AS, Heisler LK (January 2009). "Pharmacological targeting of the serotonergic system for the treatment of obesity". The Journal of Physiology. 587 (1): 49–60. doi:10.1113/jphysiol.2008.164152. PMC 2670022. PMID 19029184.
^ Jensen AA, Plath N, Pedersen MH, Isberg V, Krall J, Wellendorph P, et al. (February 2013). "Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT(2A)/5-HT(2C) receptor agonists with pro-cognitive properties". Journal of Medicinal Chemistry. 56 (3): 1211–27. CiteSeerX 10.1.1.691.154. doi:10.1021/jm301656h. PMID 23301527.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[McCall2001-1] McCall RB, Franklin SR, Hyslop DK, Knauer CS, Chio CL, Haber CL, Fitzgerald LW (2001). "PNU-22394, a 5-HT2C receptor agonist, reduced feeding in rodents and produces weight loss in humans" (Online). 27 (309.2). Presentation Number 309.2. Convention Center Exhibit Hall, Poster Board TT-45, San Diego, CA: Society for Neuroscience Abstracts. Retrieved 18 July 2014. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: location (link)

[pmid19029184-2] Garfield AS, Heisler LK (January 2009). "Pharmacological targeting of the serotonergic system for the treatment of obesity". The Journal of Physiology. 587 (1): 49–60. doi:10.1113/jphysiol.2008.164152. PMC 2670022. PMID 19029184.

[Jensen2013-3] Jensen AA, Plath N, Pedersen MH, Isberg V, Krall J, Wellendorph P, et al. (February 2013). "Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT(2A)/5-HT(2C) receptor agonists with pro-cognitive properties". Journal of Medicinal Chemistry. 56 (3): 1211–27. CiteSeerX 10.1.1.691.154. doi:10.1021/jm301656h. PMID 23301527.

[1]

[2]

[3]

PNU-22394

See also

References